rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

NextCure, Inc.

NXTC · Nasdaq

Health CareBiotechnologyNot moving yet

NXTC stood above a rising 150-day average in 26 of the last 52 weekly readings, and has been out of that trend for the last 26 weeks. It is 18.5% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 26
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$3.4M
Insider sales, 12 months
$370K
Officials’ trades on record
0
Institutions holding
27 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 26 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$3.3MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months2
Buyers · sellers1 · 2
WhoDidSharesTraded
Simcere Zaiming, Inc.Othersold30,000at $6.1610 Aug 2026filed 12 Aug 2026
Adar1 Capital Management, Llc10% ownerbought3,300at $4.9831 Jul 2026filed 3 Aug 2026
Adar1 Capital Management, Llc10% ownerbought25,000at $4.9831 Jul 2026filed 3 Aug 2026
Adar1 Capital Management, Llc10% ownerbought8,003at $4.8031 Jul 2026filed 3 Aug 2026
Adar1 Capital Management, Llc10% ownerbought50,000at $4.9730 Jul 2026filed 3 Aug 2026
Adar1 Capital Management, Llc10% ownerbought20,000at $5.0030 Jul 2026filed 3 Aug 2026
Adar1 Capital Management, Llc10% ownerbought20,000at $5.0030 Jul 2026filed 3 Aug 2026
Adar1 Capital Management, Llc10% ownerbought25,000at $4.8130 Jul 2026filed 3 Aug 2026
Adar1 Capital Management, Llc10% ownerbought100,000at $4.9030 Jul 2026filed 3 Aug 2026
Adar1 Capital Management, Llc10% ownerbought77,850at $4.9630 Jul 2026filed 3 Aug 2026
Adar1 Capital Management, Llc10% ownerbought1,810at $5.0029 Jul 2026filed 29 Jul 2026
Adar1 Capital Management, Llc10% ownerbought1,600at $5.0029 Jul 2026filed 29 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders27+5 on the quarter
New · exited12 · 7
Reported value$2.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Ikarian Capital, LLCadded · filed 14 Aug 2026288,303$461K+50,000+21.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.new · filed 14 Aug 2026277,202$444K+277,202
Sofinnova Investments, Inc.unchanged · filed 14 Aug 2026222,654$356K00.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026171,202$274K+110,668+182.8%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 2026156,842$251K+156,842
MILLENNIUM MANAGEMENT LLCnew · filed 14 Aug 202688,112$141K+88,112
BOOTHBAY FUND MANAGEMENT, LLCadded · filed 14 Aug 202684,687$135K+15,070+21.6%
Squadron Capital Management LLCreduced · filed 14 Aug 202664,464$103K-200,536−75.7%
Verdad Advisers, LPadded · filed 14 Aug 202660,451$97K+17,496+40.7%
Pfizer Increduced · filed 13 Aug 202644,347$73K-109,007−71.1%
31 Mar 2023 – 30 Jun 2026
173145Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Company insiderOther · last 10 Aug 20260 · 1
Simcere Zaiming, Inc. Company insiderOther · last 10 Aug 20260 · 1
ADAR1 Capital Management, LLC Company insider10% owner · last 31 Jul 20265 · 0
Anne Elizabeth Borgman Company insiderDirector · last 18 Jun 20260 · 0
David S. Kabakoff Company insiderDirector · last 18 Jun 20260 · 0
Elaine Jones V Company insiderDirector · last 18 Jun 20260 · 0
Ellen Feigal Company insiderDirector · last 18 Jun 20260 · 0
John G. Houston Company insiderDirector · last 18 Jun 20260 · 0
Stephen W. Webster Company insiderDirector · last 18 Jun 20260 · 0
Kevin G. Shaw Company insiderSr VP, General Counsel · last 30 Jan 20260 · 0
Michael Richman Company insiderPresident & CEO · last 30 Jan 20260 · 0
Sourav Kundu Company insiderSr VP, Dev. & Mfg. · last 30 Jan 20260 · 0

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-145%
Share count trendFY 2025 · to 27 Feb 20261.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$26.0M

Analyst forecasts

No analyst forecasts yet.